Prime Medicine and BMS Join Forces to Develop and Commercialize Various Prime Edited Ex Vivo T-Cell Therapies
Shots:
- Prime Medicine & BMS have entered into a strategic research collaboration and licensing agreement to develop reagents for next generation ex vivo T-cell therapies
- As per the agreement, Prime Medicine will develop optimized Prime Editor reagents using its PASSIGE technology for select targets while BMS will handle development, manufacturing & commercialization of next-gen cell therapies, with support from Prime Medicine
- Prime Medicine is entitled to receive $55M upfront & $55M equity investment along with an aggregate of >$3.5B milestones, incl. ~$185M preclinical, ~$1.2B development & >$2.1B commercialization milestones, plus net-sales-based royalties
Ref: Prime Medicine | Image: BMS & Prime Medicine
Related News:- BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
